Oncology

Cancer-related fatigue and depression in survivors are strongly associated with a drop in recreational physical activities and overall quality of life, according to data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

AI-based models analyzing digital pathology images may offer a major leap in pediatric sarcoma diagnosis accuracy, according to research presented at the American Association for Cancer Research Annual Meeting 2025.

Breast cancer mortality in women aged 20 to 49 has significantly declined across all racial and molecular subgroups, according to findings presented at the AACR Annual Meeting 2025 in Chicago, Illinois.

Patients with newly diagnosed, locally advanced head and neck squamous cell carcinoma (HNSCC) may soon benefit from a major shift in treatment strategy, as phase III trial data show that perioperative pembrolizumab significantly improves outcomes when added to standard care.

Promising new data emerged on zongertinib, an investigational oral therapy targeting HER2 mutations in advanced non-small cell lung cancer (NSCLC), was presented at the AACR Annual Meeting 2025 in Chicago.

At the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, new data revealed that a liquid biopsy using circulating tumor DNA (ctDNA) could detect colorectal cancer recurrence significantly earlier than imaging, with ctDNA signals appearing up to 416 days before clinical detection.

At the AACR Annual Meeting 2025 in Chicago, researchers unveiled promising early results from a novel cell therapy that could reshape treatment options for patients with relapsed or refractory acute myeloid leukemia (AML).

Neoadjuvant immunotherapy using PD-1 blockade has demonstrated the potential to eliminate the need for surgery in patients with early-stage mismatch repair-deficient (dMMR) cancers, according to groundbreaking data presented at the AACR Annual Meeting 2025.